Close Menu

depression

In Nature this week: residual protein expression uncovered for a third of CRISPR targets, and more.

The organizations noted in a letter to HHS and FDA that they "believe the agency's actions may in fact inflict greater harm on patients and impede innovation."

Researchers also uncovered associations between any psychotic experience and the genetic liability for schizophrenia, major depressive disorder, and bipolar disorder.

The firm said that UHC will cover the test for patients with major depressive disorder or anxiety who have failed to respond to one or more treatments.

In PLOS this week: networks of genes co-expressed in depression, role of minichromosome maintenance genes in lung adenocarcinoma, and more.

With $200M in new investment, the precision medicine firm has launched a clinical trial matching service, is adding clinical data to TCGA, and is moving into the Asian market.

The trials are part of the second phase of the Implementing Genomics in Practice program, which is slated to receive $42 million in funding over 5 years.

This new VC round brings the cancer informatics and precision medicine company's total fundraising to $520 million and its valuation to $3.1 billion.

Noisy Signal

The Atlantic looks into time spent pursuing gene leads generated through candidate gene studies.

To understand the evolution of brain conditions and other traits, investigators plan to sequence human and pathogen DNA in thousands of samples from Europe.

Pages

The Washington Post reports that the CDC's SARS-CoV-2 test issues reflect earlier ones it had with Zika virus testing.

Researchers traced a gene cluster linked to COVID-19 severity to Neanderthals, the New York Times reports.

NPR writes that even with thousands of new COVID-19 papers, each should be evaluated based on its own quality.

In PNAS this week: soil bacteria-derived small molecules affect centrosomal protein, microfluidics approach for capturing circulating tumor cells, and more.